• Redx Presents Encouraging Preclinical Data on the Potential of Porcupine and ROCK Inhibitors to Tackle Cancer-Associated Fibrosis

    Read more
  • Interim Results for the Six Months Ended 31 March 2022

    Read more
  • Redx to Present Preclinical Data on Three Proprietary Compounds at the Extracellular Matrix Pharmacology Congress

    Read more
  • Notice of Interim Results

    Read more
  • Jazz Pharmaceuticals and Redx Announce Pan-RAF Inhibitor JZP815 to Enter Clinical Development

    Read more
  • Redx to Present at Jefferies Global Healthcare Conference in New York

    Read more
  • Redx Presents Encouraging RXC004 Preclinical Data at the AACR Annual Meeting in Combination with Clinically Relevant Standard of Care Regimens

    Read more
  • Redx Announces Collaboration with the Garvan Institute of Medical Research

    Read more
  • Redx Nominates GI-targeted ROCK Inhibitor, RXC008, as Clinical Development Candidate

    Read more
  • Redx to Present at the American Association for Cancer Research (AACR) Annual Meeting

    Read more